EuBiologics

유바이오로직스 · 206650

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$263.4M (₩363.6B)

Overview

EuBiologics makes vaccines and biological medicines designed to prevent or treat infectious diseases.

Its products are supplied to public-health programs and medical institutions. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange. Because the filing text provided does not detail specific product lines or structural arrangements, only the company's general role as a biologics developer can be confirmed.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$108.1M

▲ +55.4% YoY

Operating profit · FY2025

US$44M

▲ +76.8% YoY

Net income · FY2025

US$29.9M

▲ +117.3% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$50.3M(₩69.4B)	US$69.6M(₩96B)	US$108.1M(₩149.2B)
Operating profit	US$5.6M(₩7.7B)	US$24.9M(₩34.3B)	US$44M(₩60.7B)
Net income	−US$11.1M(−₩15.4B)	US$13.8M(₩19B)	US$29.9M(₩41.3B)

Revenue

FY2023US$50.3M
FY2024US$69.6M
FY2025US$108.1M

Operating profit

FY2023US$5.6M
FY2024US$24.9M
FY2025US$44M

Net income

FY2023−US$11.1M
FY2024US$13.8M
FY2025US$29.9M

Key ratios (FY2025)

ROE

23.5%

Debt/Eq

37.0%

Op. margin

40.7%

Net margin

27.7%

Rev. YoY

▲ +55.4%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?